JPWO2022020353A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022020353A5 JPWO2022020353A5 JP2023504023A JP2023504023A JPWO2022020353A5 JP WO2022020353 A5 JPWO2022020353 A5 JP WO2022020353A5 JP 2023504023 A JP2023504023 A JP 2023504023A JP 2023504023 A JP2023504023 A JP 2023504023A JP WO2022020353 A5 JPWO2022020353 A5 JP WO2022020353A5
- Authority
- JP
- Japan
- Prior art keywords
- coronavirus
- ace2
- substitution
- protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711573 Coronaviridae Species 0.000 claims description 97
- 238000006467 substitution reaction Methods 0.000 claims description 93
- 229920001184 polypeptide Polymers 0.000 claims description 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 71
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 71
- 230000004927 fusion Effects 0.000 claims description 50
- 102100031673 Corneodesmosin Human genes 0.000 claims description 46
- 101710139375 Corneodesmosin Proteins 0.000 claims description 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims description 23
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 17
- 241001678559 COVID-19 virus Species 0.000 claims description 12
- 208000025721 COVID-19 Diseases 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 239000004138 Stearyl citrate Substances 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 108010087819 Fc receptors Proteins 0.000 claims description 4
- 102000009109 Fc receptors Human genes 0.000 claims description 4
- 241000315672 SARS coronavirus Species 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 230000004719 natural immunity Effects 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 229940022962 COVID-19 vaccine Drugs 0.000 claims description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 2
- 108010073807 IgG Receptors Proteins 0.000 claims description 2
- 102000009490 IgG Receptors Human genes 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- ZSRSLWKGWFFVCM-UHFFFAOYSA-N cysteinyl-proline Chemical compound SCC(N)C(=O)N1CCCC1C(O)=O ZSRSLWKGWFFVCM-UHFFFAOYSA-N 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 210000003722 extracellular fluid Anatomy 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053817P | 2020-07-20 | 2020-07-20 | |
| US63/053,817 | 2020-07-20 | ||
| US202163150686P | 2021-02-18 | 2021-02-18 | |
| US63/150,686 | 2021-02-18 | ||
| PCT/US2021/042372 WO2022020353A2 (en) | 2020-07-20 | 2021-07-20 | Methods and compositions for treatment and prevention of coronavirus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535695A JP2023535695A (ja) | 2023-08-21 |
| JP2023535695A5 JP2023535695A5 (https=) | 2024-07-30 |
| JPWO2022020353A5 true JPWO2022020353A5 (https=) | 2024-07-30 |
Family
ID=77301019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504023A Pending JP2023535695A (ja) | 2020-07-20 | 2021-07-20 | コロナウイルス感染症の治療及び予防のための方法及び組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230272359A1 (https=) |
| EP (1) | EP4182458A2 (https=) |
| JP (1) | JP2023535695A (https=) |
| KR (1) | KR20230058045A (https=) |
| CN (1) | CN116171324A (https=) |
| AU (1) | AU2021312238A1 (https=) |
| CA (1) | CA3189732A1 (https=) |
| WO (1) | WO2022020353A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| EP4132478A1 (en) | 2020-04-09 | 2023-02-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| CA3185230A1 (en) * | 2020-07-06 | 2022-01-13 | Shengjiang Liu | Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses |
| US20230374153A1 (en) * | 2022-04-13 | 2023-11-23 | Paradigm Immunoterapeutics, Inc. | METHODS OF PREVENTING OR TREATING INFECTION BY RESPIRATORY VIRUSES INCLUDING SARS-CoV-2 |
| CN119265271B (zh) * | 2024-12-09 | 2025-04-22 | 上海益诺思生物技术股份有限公司 | 一种评价ade效应的系统及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US6174530B1 (en) | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
| US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US6989363B1 (en) * | 1997-12-11 | 2006-01-24 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| WO2000070032A1 (en) * | 1999-05-13 | 2000-11-23 | Zymogenetics, Inc. | Zace2: a human metalloenzyme |
| US20040102369A1 (en) * | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
| US20070185044A1 (en) * | 2005-03-08 | 2007-08-09 | Dobie Kenneth W | Modulation of ace2 expression |
| EP1723962A1 (en) * | 2005-05-19 | 2006-11-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries |
| SG10201602394QA (en) * | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| TW201402611A (zh) * | 2012-06-21 | 2014-01-16 | Univ Indiana Res & Tech Corp | 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物 |
| HK1214652A1 (zh) * | 2013-03-13 | 2016-07-29 | 克里蒂科斯有限责任公司 | 用於检测胰腺癌的方法和组合物 |
| CN107207594B (zh) * | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| WO2021183404A1 (en) * | 2020-03-07 | 2021-09-16 | Planet Biotechnology, Inc. | Ace2-fc fusion proteins for sars-cov-2 mitigation |
| CN113444710A (zh) * | 2020-03-25 | 2021-09-28 | 上海英脉德医疗科技有限公司 | ACE2-Fc融合蛋白及其用途 |
| WO2021202427A2 (en) * | 2020-03-29 | 2021-10-07 | R-Pharm Overseas, Inc. | Ace2-derived composition and use thereof |
| JP2023526540A (ja) * | 2020-05-22 | 2023-06-21 | フォーマイコン アーゲー | Ａｃｅ２融合タンパク質及びその使用方法 |
-
2021
- 2021-07-20 KR KR1020237003077A patent/KR20230058045A/ko active Pending
- 2021-07-20 CN CN202180058122.4A patent/CN116171324A/zh active Pending
- 2021-07-20 US US18/016,209 patent/US20230272359A1/en active Pending
- 2021-07-20 CA CA3189732A patent/CA3189732A1/en active Pending
- 2021-07-20 AU AU2021312238A patent/AU2021312238A1/en active Pending
- 2021-07-20 EP EP21752830.6A patent/EP4182458A2/en active Pending
- 2021-07-20 WO PCT/US2021/042372 patent/WO2022020353A2/en not_active Ceased
- 2021-07-20 JP JP2023504023A patent/JP2023535695A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019288496B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| JP2025039660A (ja) | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 | |
| EP3144320A1 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
| CA3199447A1 (en) | Fusions with cd8 antigen binding molecules for modulating immune cell function | |
| AU2022200528A1 (en) | Antibody-cytokine engrafted proteins and methods of use for immune related disorders | |
| US20250009854A1 (en) | Antiviral Agent Comprising a Cellular Entry Receptor and Fc Region Component | |
| CA3170338A1 (en) | Engineered anti-her2 bispecific proteins | |
| KR20230129423A (ko) | 면역 세포 기능 조절을 위한 항원 결합 분자와 돌연변이인터루킨-10 폴리펩티드의 융합 | |
| KR20230141839A (ko) | 전하쌍을 갖는 이중 특이성 항체 및 이의 용도 | |
| JPWO2022020353A5 (https=) | ||
| JP2024544531A (ja) | 位置４２９に変異を有するｆｃ領域成分を含む免疫療法タンパク質 | |
| CA3218571A1 (en) | Methods of screening and expression of disulfide-bonded binding polypeptides | |
| WO2013013029A1 (en) | Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes | |
| CN120112558A (zh) | 治疗慢性病毒感染的含cd8抗原结合分子的融合物 | |
| KR102725210B1 (ko) | 안정화된 Ace2 변이체, 이를 이용한 Ace2-Fc 융합단백질 및 COVID-19 예방 또는 치료용 약학 조성물 | |
| AU2020270242B2 (en) | Anti-TNF-α humanized monoclonal antibody TCX060 having low immunogenicity and low ADCC/CDC function, and use thereof | |
| JPWO2021003469A5 (https=) | ||
| EP4671273A1 (en) | INTERLEUKIN 21 PROXIMITY ACTIVATED | |
| WO2024229535A1 (en) | Immunotherapeutic proteins | |
| JPWO2022109313A5 (https=) | ||
| CN115724985A (zh) | 一种cdc平台抗体 | |
| CN117015556A (zh) | 带电荷对的双特异性抗体及其应用 | |
| WO2025076440A1 (en) | TGFβRII EXTRACELLULAR REGION VARIANTS AND USES THEREOF | |
| CN116813789A (zh) | 一种广谱中和新冠病毒Omicron亚变种的全人源双特异性抗体 |